Literature DB >> 8541299

Liposome clearance from blood: different animal species have different mechanisms.

D Liu1, Q Hu, Y K Song.   

Abstract

The kinetics of blood clearance and the mechanisms of liposome uptake by the reticuloendothelial system (RES) were compared in two animal species (mice and rats). By employing an in situ liver perfusion technique with selected liposome compositions (PC/Chol, PC/Cho/PS, PC/Chol/GM1 and PC/Chol/PEG5000-PE), we demonstrated that liposomes with same lipid composition exhibited different blood circulation half-lives in different animal species. Although liver is the major organ responsible for the clearance of liposomes from blood in both animal species, the specific mechanisms differ. In mice, liposome uptake by the liver did not involve specific serum opsonins. In contrast, liposome uptake by the rat liver was strongly dependent on serum opsonins. Further, the activity of serum opsonins for a given liposome composition differed among animal species. Human serum exhibited higher opsonin activities for PC/Chol and PC/Chol/GM1 liposomes than bovine sera, while rat serum displayed a high opsonizing activity for GM1 liposomes and none for liposomes composed of PC and Chol. The opsonin activity of human serum could be removed or decreased by treatment with EGTA/Mg2+, EDTA or cobra venom factor, suggesting that the activity is likely due to complement components. It is likely that C3 of the human complement system plays an important role in mediating the uptake of liposomes by the liver.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541299     DOI: 10.1016/0005-2736(95)00184-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

2.  Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition.

Authors:  Leonid Kagan; Pavel Gershkovich; Kishor M Wasan; Donald E Mager
Journal:  Pharm Res       Date:  2013-06-21       Impact factor: 4.200

Review 3.  Challenges in development of targeted liposomal therapeutics.

Authors:  Rupa R Sawant; Vladimir P Torchilin
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

4.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

Review 5.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

6.  Fluorescent ampicillin analogues as multifunctional disguising agents against opsonization.

Authors:  Nalinikanth Kotagiri; Joshua Sakon; Haewook Han; Vladimir P Zharov; Jin-Woo Kim
Journal:  Nanoscale       Date:  2016-03-03       Impact factor: 7.790

7.  Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.

Authors:  Yu-Li Lo; Yu Liu
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

Review 8.  Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans.

Authors:  Michael S Valic; Gang Zheng
Journal:  Theranostics       Date:  2019-05-18       Impact factor: 11.556

Review 9.  Efficient hepatic delivery of drugs: novel strategies and their significance.

Authors:  Nidhi Mishra; Narayan Prasad Yadav; Vineet Kumar Rai; Priyam Sinha; Kuldeep Singh Yadav; Sanyog Jain; Sumit Arora
Journal:  Biomed Res Int       Date:  2013-10-28       Impact factor: 3.411

10.  γ-Tocotrienol-Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs.

Authors:  Sang-Gyu Lee; Teja Muralidhar Kalidindi; Hanzhi Lou; Kishore Gangangari; Blesida Punzalan; Ariana Bitton; Casey J Lee; Hebert A Vargas; Soobin Park; Lisa Bodei; Michael G Kharas; Vijay K Singh; Naga Vara Kishore Pillarsetty; Steven M Larson
Journal:  J Nucl Med       Date:  2020-08-21       Impact factor: 11.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.